What is the purpose of the Azacitidine 100mg Injection Azacytin?
Azacitidine 100mg Injection Azacytin Patients with subtypes of French-American-British (FAB) myelodysplastic syndrome, such as refractory anemia or chronic leukemia, are treated with azacitidine injection. Azacitidine is a type of medication called a metabolite. It stops cancer cells from multiplying, causing them to die.
Is azacitidine a chemotherapeutic agent?
Azacitadine is a cytotoxic chemotherapeutic medication. This drug is classified as a demethylating agent and an antimetabolite (for more details, see “How Azacitadine Works” below).
Can you take Azacitidine 100mg Injection Azacytin for a long time?
Patients should be treated with azacitidine for at least 6 months, and treatment should be continued in patients who achieve a documented response or stable disease (sd) until disease progression or unacceptable toxicity occurs.
Is there a difference between azacitidine and Vidaza?
Azacitidine, also known by its brand name, Vidaza, is a cancer medication. It is a treatment for those who are unable to get high-dose stem cell transplant treatment for the following conditions: Chronic myelomonocytic leukemia is a type of leukemia that affects the blood cells (CMML).
Is it true that azacitidine causes hair loss?
Hair loss is common after the first or second treatment. It’s nearly always only temporary, and your hair will regrow after the therapy is over.
What are the azacitidine side effects?
Azacitidine has the potential to induce adverse effectsContact your doctor if any of these symptoms become severe or do not go away:
- diarrhea, constipation.
- sores on the tongue or in the mouth.
- Tenderness or soreness in the stomach.
- heartburn. heart, liver, and kidney. For more details Click Here.
Is azacitidine used for what?
VIDAZA is used to treat patients with the following subtypes of myelodysplastic syndrome: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in children, and refractory anemia with excess blasts in children.
Is azacitidine a specific treatment?
Nonetheless, many novel epigenetic-modifying medications are mechanism-targeted rather than mutation-targeted, and most have shown low toxicity to date. The drugs decitabine and 5-azacitidine, which are standard therapy for MDS and also demonstrate strong clinical activity in AML, are included in this list.